哈药集团股份有限公司关于控股股东部分股份解除质押及质押的公告

Core Points - The announcement details the share pledge and release situation of Harbin Pharmaceutical Group Co., Ltd. (the "Company") and its controlling shareholder, Harbin Pharmaceutical Group Limited [2][5] - As of the announcement date, Harbin Pharmaceutical Group Limited holds 1,173,237,023 shares, representing 46.58% of the Company's total share capital [2] - After the recent transactions, a total of 844,275,562 shares are pledged, which accounts for 71.96% of the shares held by Harbin Pharmaceutical Group Limited and 33.52% of the Company's total share capital [2] Share Release Situation - Harbin Pharmaceutical Group Limited has completed the release of 287,581,686 shares previously pledged to Bank of China Macau Branch [2] - Some of the released shares will be used for subsequent pledges [2] Share Pledge Situation - The total number of pledged shares by Harbin Pharmaceutical Group Limited exceeds 50% of its holdings [4] - Within the next six months, 400,439,952 shares will mature, representing 34.13% of the shares held and 15.90% of the Company's total share capital, with a corresponding financing balance of $80 million [5] Financial Health and Impact - The funds raised from the share pledge are primarily for the operational needs of Harbin Pharmaceutical Group Limited, which maintains good credit and financial status [5] - The pledge will not affect the Company's operations, financing costs, or governance structure, and there will be no changes in the board of directors [6] - The pledge does not involve any major asset restructuring or performance compensation obligations [6]